4CPS-034 Effectiveness and safety of monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (pcsk9 inhibitors) for the treatment of hypercholesterolaemia

H Quiros Ambel; C Donoso Rengifo; AA García Sacristán; JM Martinez Sesmero; A Dominguez Barahona; S González Suarez; P Moya Gomez; C Blazquez Romero

doi:10.1136/ejhpharm-2018-eahpconf.125

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Section 4: Clinical pharmacy services

4CPS-034 Effectiveness and safety of monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (pcsk9 inhibitors) for the treatment of hypercholesterolaemia

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Ambel HQ, Rengifo CD, Sacristán AG, et al

4CPS-034 Effectiveness and safety of monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (pcsk9 inhibitors) for the treatment of hypercholesterolaemia

European Journal of Hospital Pharmacy 2018;25:A56-A57.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password